Longer Survival for Black vs White Myeloma Patients With Same Care
Black people with multiple myeloma live longer than white patients with similar disease symptoms when both receive the same new and updated medical treatments,…
Steve Bryson, PhD, science writer — 
Articles by Steve Bryson
Sarclisa Extends Survival in RRMM, Long-term Phase 3 Trial Data Shows
The therapy Sarclisa (isatuximab) extended survival by nearly seven months in relapsed/refractory multiple myeloma patients also given Pomalyst (pomalidomide) and dexamethasone as standard…
FDA Approves 8th Darzalex Faspro Indication for Myeloma Patients
The U.S. Food and Drug Administration (FDA) has approved Darzalex Faspro (daratumumab and hyaluronidase), in combination with Kyprolis (carfilzomib) and the corticosteroid dexamethasone,…
Blood Type O Lowers Myeloma Risk, But Outcomes Typically Worse
People with blood type O are significantly less likely to develop multiple myeloma, but those who do are…
China Approves Xgeva to Prevent Bone Events Due to Multiple Myeloma, Other Cancers
Xgeva (denosumab) has been approved by the China National Medical Products Administration (NMPA) to prevent…
Radiation Therapy Safe for Myeloma Patients Before CAR T-cell Infusion, Study Finds
Administering radiation therapy to people with relapsed or refractory (resistant) multiple myeloma waiting for CAR T-cells to…
Melflufen Open to Select Adults With Advanced Multiple Myeloma in US
Oncopeptides has formally opened sEAPort, its open-label expanded access program allowing adults with…
CHMP Favors Darzalex Faspro in Treating Patients in EU
Janssen‘s new under-the-skin formulation of daratumumab, called Darzalex Faspro, has been recommended for approval…
Gains in 5-Year Survival with Stem Cell Transplant Evident Since Late ’90s
The long-term survival of people with multiple myeloma following autologous stem cell transplant has steadily improved since 1997…
New CAR T-cell Therapy Shows Early Promise Against Multiple Myeloma in Lab Study
A new CAR T-cell therapy  for people with multiple myeloma has been successfully created and tested in…